The Methylenetetrahydrofolate Reductase 677C→T Polymorphism and Distal Colorectal Adenoma Risk

A common polymorphism in the methylenetetrahydrofolate reductase ( MTHFR ) gene, where a cytosine at nucleotide 677 is replaced by a thymine (677C→T), is associated with enzyme thermolability and a reduction in the conversion of 5,10-methyltetrahydrofolate (5,10-MTHF) into 5-methyltetrahydrofolate. We assessed the association between homozygosity for the MTHFR 677CT genotype ( TT ) and colorectal adenoma risk in a large sigmoidoscopy-based case-control study of members of a prepaid health plan in Los Angeles. MTHFR genotype was determined for 471 cases and 510 age-, sex-, clinic-, and sigmoidoscopy-date-matched controls. Information on RBC and plasma folate levels were analyzed for 331 cases and 350 controls. When compared with the presence of at least one wild-type allele ( CT/CC ), the odds ratio (OR) for the TT genotype was 1.19 [95% confidence interval (CI), 0.77–1.76] after adjusting for race and the matching factors. Compared with those in the lowest quartiles of RBC and plasma folate and a wild-type allele, adenoma risk was increased for TT homozygotes in the lowest folate quartiles (genotype: OR, 2.04 and 95% CI, 0.6–7.0; OR, 1.84 and 95% CI, 0.6–7.0 for RBCs and plasma folate, respectively) and decreased in TT homozygotes in the highest quartiles (genotype: OR, 0.82 and 95% CI, 0.32–2.10; OR, 0.65 and 95% CI, 0.22–1.95, respectively). There was also a significant interaction between TT genotype and the increased adenoma risk associated with alcohol. These data are consistent with an interaction between MTHFR genotype and folate availability.